Mutual of America Capital Management LLC Buys 1,604 Shares of Enovis Co. (NYSE:ENOV)

Mutual of America Capital Management LLC raised its stake in Enovis Co. (NYSE:ENOV) by 5.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,183 shares of the company’s stock after purchasing an additional 1,604 shares during the period. Mutual of America Capital Management LLC owned 0.05% of Enovis worth $1,299,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ENOV. River Road Asset Management LLC acquired a new position in Enovis in the 3rd quarter valued at $51,341,000. American Century Companies Inc. grew its stake in shares of Enovis by 78.6% in the second quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock valued at $68,337,000 after acquiring an additional 665,208 shares in the last quarter. Magnetar Financial LLC grew its stake in shares of Enovis by 66.7% in the second quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company’s stock valued at $49,937,000 after acquiring an additional 442,051 shares in the last quarter. Diamond Hill Capital Management Inc. increased its position in Enovis by 14.5% during the second quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company’s stock worth $125,929,000 after acquiring an additional 352,116 shares during the period. Finally, Royce & Associates LP raised its stake in Enovis by 16.8% in the 3rd quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock worth $103,479,000 after purchasing an additional 346,317 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ENOV. Evercore ISI decreased their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 1st. JMP Securities assumed coverage on Enovis in a research note on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price objective on the stock. JPMorgan Chase & Co. cut their target price on Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $65.00 target price on shares of Enovis in a report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $67.00.

Enovis Trading Up 3.4 %

ENOV opened at $48.27 on Tuesday. The company has a market cap of $2.70 billion, a P/E ratio of -22.04 and a beta of 1.91. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The company’s 50 day moving average is $42.70 and its 200-day moving average is $44.92. Enovis Co. has a 1-year low of $38.27 and a 1-year high of $65.03.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. During the same period in the prior year, the business earned $0.56 earnings per share. The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. Equities research analysts predict that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.